Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celleron licenses cancer lead from AstraZeneca

This article was originally published in Scrip

Executive Summary

UK-based Celleron Therapeutics has secured exclusive rights to AstraZeneca's histone deacetylase inhibitor AZD-9468. Celleron plans to develop the drug (now to be known as CXD101) in conjunction with their "CancerNav" predictive biomarker platform, which they hope can be used to identify susceptible tumours. Celleron will lead the clinical trials, which have yet to start, and AstraZeneca will receive significant milestones, royalties and additional share of financial proceeds in the event of successful commercialisation by a third party.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts